Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer

Tumori

Volumn 98, Issue 3, 2012, Pages 364-369

  Ruiz Tovar, Jaime ^a   Fernandez Contreras, Maria Encarnacioń ^b   Martiń Perez, Elena ^b   Gamallo, Carlos ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

DNA polymorphism; Hypoxia inducible factor 1 ; Pancreatic cancer; Thymidylate synthase

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; THYMIDYLATE SYNTHASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GC RICH SEQUENCE; GENE; GENE DELETION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HYPOXIA INDUCIBLE FACTOR 1ALPHA GENE; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; THYMIDYLATE SYNTHASE GENE; VARIABLE NUMBER OF TANDEM REPEAT;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; MINISATELLITE REPEATS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84867085897     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800314     Document Type: Article

References (29)

1. Gawron AJ, Gapstur SM, Fought AJ, Talamonti MS, Skinner HG: Sociodemographic and tumour characteristics associated with pancreatic cancer surgery in the United States. J Surg Oncol, 97: 578-582, 2008. (Pubitemid 351794146)
2. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg, 237: 74-85, 2003. (Pubitemid 36622320)
3. Wang L, Miao X, Tan W, Lu X, Zhao P, Zhao X, Shan Y, Li H, Lin D: Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol, 3: 743-751, 2005. (Pubitemid 41116726)
4. Couvelard A, O'Toole D, Leek R: Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology, 46: 668-676, 2005. (Pubitemid 40834826)
5. Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, Ahrendt SA: Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res, 9: 4983-4991, 2003.
6. Sharp L, Little J: Polymorphisms in genes involved in folate metabolism and colorectal neoplasia. A huge review. Am J Epidemiol, 159: 423-443, 2004. (Pubitemid 38280289)
7. Kawakami K, Omura K, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene associated with its protein expression in human gastrointestinal cancers. Anticancer Res, 19: 3249-3252, 1999. (Pubitemid 30042617)
8. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL: Expression of hypoxia-inducible factor 1 alpha in brain tumours. Association with angiogenesis, invasion and progression. Cancer, 88: 2606-2618, 2000. (Pubitemid 30331970)
9. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res, 59: 5830-5835, 1999.
10. Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER: The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx and Hif-1 alpha in renal cell carcinoma. Oncogene, 20: 5067-5074, 2001. (Pubitemid 32769798)
11. Fransen K, Fenech M, Fredrikson M, Dabrosin C, Söderkvist P: Association between ulcerative growth and hypoxia inducible factor-1 alpha polymorphisms in colorectal cancer patients. Molecular Carcinogenesis, 45: 833-840, 2006. (Pubitemid 44646335)
12. Fernández-Contreras ME, Sánchez-Prudencio S, Sánchez-Hernández JJ, García de Paredes ML, Gisbert JP, Roda-Navarro P, Gamallo C: Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol, 28: 1303-1310, 2006.
13. Muñoz-Guerra MF, Fernandez-Contreras ME, Capote Moreno AL, Dominguez Martin I, Herraez B, Gamallo C: Polymorphisms in the hypoxia inducible factor 1α and the impact on the prognosis of early stages oral cancer. Ann Surg Oncol, 16: 2351-2358, 2009.
14. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev, 9: 1381-1385, 2000. (Pubitemid 32044809)
15. Fernández-Contreras ME, Sánchez-Hernández JJ, González E, Herráez B, Domínguez I, Lozano M, García De Paredes ML, Muñoz A, Gamallo C: Combination of polymorphisms within 5′ and 3′ untranslated regions of thymidylate synthase gene modulates survival in 5 fluo-rouracil-treated colorectal cancer patients. Int J Oncol 34: 219-229, 2009.
16. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthesis. Cell Struct Funct, 20: 191-217, 1995.
17. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, Rollinson S, Roman E, Cartwright RA, Morgan GJ: Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood, 99: 3786-3791, 2002. (Pubitemid 34534552)
18. Hishida A, Matsuo H, Hamajima N: Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica, 88: 159-166, 2003. (Pubitemid 37101493)
19. Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumour sensivity to 5-fluorouracil-baed oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res, 9: 3700-3704, 2003. (Pubitemid 37169238)
20. Lee J, Jeong CK, Hong SP: Clinical significance of thymidylate synthase and methylentetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer. Korean J Gastroenterol, 46: 32-38, 2005.
21. Chen J, Hunter DJ, Stampfer MJ, Kyte C, Chan W, Wetmur JG, Mosig R, Selhub J, Ma J: Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 12: 958-962, 2003. (Pubitemid 37310249)
22. Fernández-Contreras ME, Sánchez-Hernández JJ, Guijarro M, Gisbert JP, Rivas N, García de Paredes ML, Hinojar-Gutiérrez A, Gamallo C: Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Oncol Rep, 23: 1393-1400, 2010.
23. HapMap Project. CEPH population. Available at URL: http://www.ncbi.nih. gov/SNP/snp-ref.cgi?rs=11549467.
24. Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A: An investigation of relationships between hypoxia-inducible factor-1-α gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect Prev, 31: 102-109, 2007. (Pubitemid 46680371)
25. Dong ZM, Cui YJ, Kuang G, Wang R, Yu FL, Zhang JH: Polymorphisms of thymidylate synthase gene and correlation of its protein expression to lymph node metastasis of esophageal squamous cell carcinoma. Ai Zheng, 24: 1225-1229, 2005.
26. Takehara A, Kawakami K, Ohta N, Oyama K, Ota Y, Oda M, Watanabe G: Prognostic significance of the polymorphisms in thymidylate synthase and methylentetrahydofolate reductase gene in lung cancer. Anticancer Res, 25: 4455-4461, 2005. (Pubitemid 41729496)
27. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M: Hypoxia-inducible factor-1 alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis, 24: 1779-1783, 2003. (Pubitemid 37408141)
28. Fu XY, Choi E, Bubley GJ: Identification of hypoxia-inducible factor-1 α (HIF-1 α) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate, 63: 215-221, 2005. (Pubitemid 40571055)
29. Masson N, William C, Maxwell PH: Independent function of two destruction domains in hypoxia-inducible factor alpha chains activated by prolyl hydroxilation. EMBO J, 20: 5197-5206, 2001. (Pubitemid 32910914)